Seattle Genetics, Inc. and Genmab A/S have entered into an additional antibody-drug conjugate (ADC) collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive ...

COPENHAGEN, Sept 14 (Reuters) - Danish biotech company Genmab A/S will collaborate in cancer drug research with Seattle Genetics under a strategy to focus on strategic partnerships for drug ...

A pivotal trial of Seattle Genetics' experimental cancer-targeting antibody for patients with Hodgkin's lymphoma found that more than a third of them achieved complete remission of their cancer. The ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS ...

-Collaboration Combines Seattle Genetics’ Expertise in Cancer Targets and Antibody-Based Therapies with Unum’s Novel Antibody-Coupled T-cell Receptor (ACTR) Technology- -Companies to Focus on the ...

LOS ANGELES, Sept 24 (Reuters) - Biotechnology company Seattle Genetics will announce on Monday results from a pivotal trial of experimental drug brentuximab vedotin in patients with Hodgkin lymphoma.

Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago. These figures are ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Seattle Genetics (SGEN) reports results for the quarter ended September 2023. While this widely-known consensus ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Drug development partner Takeda is paying Seattle Genetics ...